LYMPHOMA, T CELL, PERIPHERAL
Clinical trials for LYMPHOMA, T CELL, PERIPHERAL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T CELL, PERIPHERAL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T CELL, PERIPHERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in Hard-to-Treat blood cancer
Disease control Recruiting nowThis phase 3 trial tests a new oral drug, soquelitinib, against standard single-agent chemotherapy in 150 adults with relapsed or refractory peripheral T-cell lymphoma. The study aims to see if soquelitinib can delay cancer progression better than current options. Participants ar…
Matched conditions: LYMPHOMA, T CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New targeted drug combo aims to fight rare lymphoma
Disease control Recruiting nowThis phase 3 trial is testing whether adding the targeted drug tucidinostat to standard CHOP chemotherapy helps people with a rare form of lymphoma called peripheral T-cell lymphoma with TFH phenotype. About 224 newly diagnosed adults will receive either tucidinostat or a placebo…
Matched conditions: LYMPHOMA, T CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:20 UTC